IIB

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

Retrieved on: 
Tuesday, August 15, 2023
Patent, IIB, Therapy, Marketing, Public, United States Patent and Trademark Office, COVID-19, Urinary tract infection, Malaria, Infection, COVID, Risk, ClinicalTrials.gov, Degree, HIV disease progression rates, Patient, Standard of care, Public health, Ageing, FDA, IND, Disease, Tafenoquine, Pharmaceutical industry

The trial will be conducted by 60P’s majority-owned subsidiary, 60P Australia Pty Ltd, which opened a new IND on August 14, 2023.

Key Points: 
  • The trial will be conducted by 60P’s majority-owned subsidiary, 60P Australia Pty Ltd, which opened a new IND on August 14, 2023.
  • “Publicly registering ACLR8-LR represents an important milestone in 60P’s clinical research strategy,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow.
  • In April, the United States Patent and Trademark Office (USPTO) issued a patent covering the use of tafenoquine as a treatment for COVID-19 disease.
  • 60P now owns the exclusive rights for the use of tafenoquine for treatment of lung infections including COVID-19 in the U.S. through 2040.

Elevate Your Patent Game: Advanced Drafting Techniques for Successful EPO (European Patent Office) Patent Applications Training Course (London, UK - November 10, 2023)

Retrieved on: 
Friday, August 18, 2023
Daniel, International Patent Institute, IIB, Mechanics, Success, Electronics, DG2, Disclosure, The Hague, University, Representation before the European Patent Office, Computer, Marketing Research Institute International, EPO, CEIPI, Patent, European Patent Convention, Physics, Knowledge, DG1, Industrial design

DUBLIN, Aug. 18, 2023 /PRNewswire/ -- The "Advanced Drafting Techniques for Successful EPO (European Patent Office) Patent Applications Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 18, 2023 /PRNewswire/ -- The "Advanced Drafting Techniques for Successful EPO (European Patent Office) Patent Applications Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • Many patent applications and patents are lost before the EPO, either before Opposition Divisions or before Appeal.
  • The interplay between Art 83, Art 84 and Art 56
    Daniel X. Thomas is an electronics engineer by training.
  • Although he retired from active service at the EPO on 1 January 2013, Daniel continues to be active in the field of training patent specialists.

Xiaomi to Showcase MIUI Themes Designers Via 2023 Xiaomi International Theme Competition

Retrieved on: 
Tuesday, August 1, 2023
IIB, International, Kenneth Matiba, Electronics, Smartphone, Culture, Language, USD, Creativity, MIUI, GNOME Core Applications, Mobile phone

BEIJING, Aug. 1, 2023 /PRNewswire/ -- Xiaomi, one of the world's leading consumer electronics and smart manufacturing companies, officially started its 2023 Xiaomi International Theme Competition on Friday.

Key Points: 
  • BEIJING, Aug. 1, 2023 /PRNewswire/ -- Xiaomi, one of the world's leading consumer electronics and smart manufacturing companies, officially started its 2023 Xiaomi International Theme Competition on Friday.
  • With the slogan "Global Expressions, Local Inspirations", the competition aims to attract more designers from the markets where Xiaomi operates and generate more themes incorporating local designs and motifs for Xiaomi users worldwide.
  • The International Theme Competition is a key branding campaign for Xiaomi's international internet business, which conveys our commitment to building a customized, enjoyable MIUI for everyone."
  • Here, MIUI Theme plays a central role — thousands of new themes are designed and uploaded daily by both professional creatives and passionate Xiaomi Fans.

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Retrieved on: 
Friday, July 21, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, IIB, Civil service commission, European Medicines Agency, Cancer, European Directive on Traditional Herbal Medicinal Products, European Commission, BMY, Committee, EMA, Patient, Lymph, Checkmate, Risk, Melanoma, Annual general meeting, European, IIC, SMR, Committee for Medicinal Products for Human Use, PD-1, Melanoma Research, Recurrence, EC, III, Death, Nivolumab, NYSE, Disease, Safety, CHMP, Vaccine, Pharmaceutical industry, EU

If approved, Opdivo would become the only PD-1 inhibitor that - between two approvals* - is indicated as an adjuvant treatment for patients within stages IIB, IIC, III, as well as stage IV resected melanoma.

Key Points: 
  • If approved, Opdivo would become the only PD-1 inhibitor that - between two approvals* - is indicated as an adjuvant treatment for patients within stages IIB, IIC, III, as well as stage IV resected melanoma.
  • The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation.
  • “Many patients with stage IIB or stage IIC melanoma face the difficult reality of disease recurrence within five years of surgery,” said Gina Fusaro, Ph.D., vice president, global program lead, Bristol Myers Squibb.
  • “In the data from the CheckMate -76K trial, Opdivo was shown to significantly reduce the risk of disease recurrence for these patients.

Risk Strategies Acquires International Insurance Brokers, Ltd.

Retrieved on: 
Tuesday, May 2, 2023
IIB, Risk management, Transport, Insurance, International Insurance Company, Risk, Financial services

BOSTON, May 02, 2023 (GLOBE NEWSWIRE) -- Risk Strategies , a leading national specialty insurance brokerage and risk management firm, today announced it has acquired International Insurance Brokers, Ltd. (IIB), a full-service retail agency based in Tulsa, Oklahoma.

Key Points: 
  • BOSTON, May 02, 2023 (GLOBE NEWSWIRE) -- Risk Strategies , a leading national specialty insurance brokerage and risk management firm, today announced it has acquired International Insurance Brokers, Ltd. (IIB), a full-service retail agency based in Tulsa, Oklahoma.
  • “We’re building out our central region presence as a specialist that brings a client-first, business savvy approach to risk and liability management,” said Steve Giannone, Risk Strategies Central Regional Leader.
  • “International Insurance Brokers is a great fit for us and this approach to expanding our capabilities without compromise.”
    International Insurance Broker’s comprehensive and systematic approach to risk management and protection has engendered strong loyalty and retention among its customer base.
  • To learn more about Risk Strategies, please visit www.riskstrategies.com .

60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections

Retrieved on: 
Wednesday, April 26, 2023
IIB, Therapy, Marketing, Public, COVID-19, Urinary tract infection, Infection, Risk, State, Tafenoquine, HIV disease progression rates, Patient, Standard of care, Public health, Ageing, Phase, FDA, Disease, Malaria, Pharmaceutical industry, Patent

Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections.

Key Points: 
  • Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections.
  • Data from a Phase II study completed last year suggest a positive therapeutic signal in mild-moderate COVID-19 disease using the ARAKODA regimen of tafenoquine.
  • WASHINGTON, April 26, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals (“60P”), specialists in developing and marketing medicines for infectious diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of tafenoquine as a treatment for COVID-19 disease.
  • 60P now owns the exclusive rights for the use of tafenoquine for treatment of viral lung infections including COVID-19 in the U.S. through 2040.

Xiaomi Presents its Customer Success Solutions with Xapads at the Game Developers Conference

Retrieved on: 
Friday, March 31, 2023
IIB, MAU, International, Partner (business rank), Original equipment manufacturer, CTV, Android, GDC, Go Out policy, Mobile, UA, Acquisition, Advertising, Game Developers Conference, SAN, Mom, Growth, Commercial, Ecosystem, OEM, ROI, Conference, Mobile World Congress, Mobile phone, MIUI

SAN FRANCISCO, March 31, 2023 /PRNewswire/ -- Xiaomi's International Internet Business Department (IIB), the global strategic internet business arm of the Chinese smartphone company, presented its customer success solutions for game developers in collaboration with Xapads, a leading digital marketing platform at the Game Developers Conference (GDC) in San Francisco last week.

Key Points: 
  • SAN FRANCISCO, March 31, 2023 /PRNewswire/ -- Xiaomi's International Internet Business Department (IIB), the global strategic internet business arm of the Chinese smartphone company, presented its customer success solutions for game developers in collaboration with Xapads, a leading digital marketing platform at the Game Developers Conference (GDC) in San Francisco last week.
  • Both parties revealed their competitive advantages in boosting user growth, offering a brand new and one-stop solution package for game developers.
  • With OEMs, especially Xiaomi, Xapads helped an online game platform customer to gain 11.7 million clicks and over 217,000 installs.
  • For another game platform customer, Xapads and Xiaomi generated 22.4 million clicks and 5.3 million installs, and the signup rate and first deposit rate were also significantly increased.

Xiaomi Holds MWC Workshop to Show How Game Partnership Can Give Exposure to Millions of MIUI Users

Retrieved on: 
Tuesday, March 7, 2023
Logic, MWC, Ecosystem, Mobile World Congress, IIB, International, Mobile Legends: Bang Bang, Partnership, MIUI, Policy, Happiness, MLBB, Mobile phone, Medical device, Video game

BARCELONA, Spain, March 7, 2023 /PRNewswire/ -- Xiaomi's International Internet Business Department (IIB), the global strategic internet business arm of the Chinese smartphone company, recently held a workshop at the Mobile World Congress (MWC), which took place in Barcelona, to demonstrate how its MIUI platform can give game developers exposure to millions of potential global users.

Key Points: 
  • Mobile game developers in Europe can now partner with Xiaomi's International Internet Business Department to gain system-level exposure, boosting their user growth.
  • While in Europe, IIB's team also visited a series of game developers in the UK, Germany, and France to explore opportunities in game partnerships.
  • By Q3 of 2022, the monthly active users of MIUI had surpassed 563 million globally.
  • Xiaomi's partnership with popular mobile game Mobile Legends: Bang Bang (MLBB) shows exactly what IIB can attribute to user growth for game developers.

Xiaomi's International Internet Business Announces its "Go Global" Strategy at MWC

Retrieved on: 
Monday, March 6, 2023
Online, OS, Electronics, MWC, Television, Ecosystem, Taboola, Marketing, Acquisition, Mobile World Congress, Internet, IIB, International, Partnership, MIUI, OEM, Calendar, Smartphone, Go Out policy, Mobile, MLBB, Video game, Mobile phone, Medical device

BARCELONA, Spain, March 6, 2023 /PRNewswire/ -- Xiaomi's International Internet Business Department (IIB), the global internet business arm of the Chinese consumer electronics manufacturer, wrapped up their showing at the Mobile World Congress (MWC), one of the biggest events in the calendar for the global mobile technology industry, by announcing its "Go Global" strategy for the year 2023, expanding its cooperative relationships with global partners and exploring new business opportunities in internet services.

Key Points: 
  • We're very excited to be here in Barcelona to reach a wider audience, and turn possibilities into opportunities for success," said Chan Liu, General Manager, International Internet Business Dept., Xiaomi.
  • The sizable user base empowers Xiaomi's international internet business across multiple regions, such as app and game distribution, content integration services, user growth, and customer success.
  • "The cooperation with Xiaomi's International Internet Business Team has granted us fast and direct accesses to millions of MIUI users around the world.
  • For more information about Xiaomi's International Internet Business and to contact us, you can follow our LinkedIn at https://www.linkedin.com/company/mi-ads/

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….

Retrieved on: 
Tuesday, February 28, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, SMR, Safety, PDUFA, Bristol Myers Squibb, Society, Doctor of Philosophy, Cancer, Melanoma Research, NYSE, BMY, Disease, Nivolumab, Lung cancer, Recurrence, European Medicines Agency, RFS, Annual general meeting, IIB, Bladder cancer, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IIC, EMA, NSCLC, Type, MAA, Food, Melanoma, Checkmate, Pharmaceutical industry, Medical device

In the U.S., the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of October 13, 2023.

Key Points: 
  • In the U.S., the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of October 13, 2023.
  • In Europe, the EMA’s validation of the application confirms the submission is complete and begins the start of the EMA’s centralized review process.
  • “Melanoma can be a devastating diagnosis, and patients with stage IIB or IIC melanoma tend to be at high risk of disease recurrence.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -76K trial.